Banco Santander SA (SAN)

4.99
0.06 1.10
NYSE : Financial
Prev Close 4.93
Open 4.97
Day Low/High 4.96 / 4.99
52 Wk Low/High 3.60 / 5.22
Volume 1.92M
Avg Volume 5.68M
Exchange NYSE
Shares Outstanding 14.43B
Market Cap 67.26B
EPS 0.40
Div & Yield 0.20 (4.30%)

Latest News

RBS Fails Bank of England Stress Tests, Pledges New Capital Plan

RBS Fails Bank of England Stress Tests, Pledges New Capital Plan

RBS misses both key targets in Bank of England tests, says it must "do more" to restore resilience.

Banco Santander Stock Rises on Shareholder Payout Bets After ECB Capital Report

Banco Santander Stock Rises on Shareholder Payout Bets After ECB Capital Report

A less stringent ECB capital target has investors betting on a bigger payout for shareholders.

New Survey Finds Men In The U.S. Want To Take Charge Of Their Own Health And Wellness

New Survey Finds Men In The U.S. Want To Take Charge Of Their Own Health And Wellness

Data also Shows Men Consider Sexual Health to be an Important Priority

There's Still Time to Buy These 5 Big-Cap Breakouts

There's Still Time to Buy These 5 Big-Cap Breakouts

Here's a technical look at how to trade some of the biggest stocks on Wall Street, including Texas Instruments, Schlumberger and Exxon Mobil.

Poste Italiane Courts UniCredit's $3.2 Billion Pioneer Asset Manager

Poste Italiane Courts UniCredit's $3.2 Billion Pioneer Asset Manager

The postal services operator will merge its fund management unit with bid partner Anima to bulk up for the offer.

European Bank Stocks Fall as Trump Win Highlights Business Risks

European Bank Stocks Fall as Trump Win Highlights Business Risks

The prospect of a trade spat with China puts HSBC in the spotlight as Deutsche Bank wilts on regulation worries.

BBVA & Banco Santander: Two of Europe's Biggest Losers From Trump's Presidency

BBVA & Banco Santander: Two of Europe's Biggest Losers From Trump's Presidency

Significant exposures to Mexico, as well as European economies, leave both bank stocks reeling.

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...

Santander's Business Banking Customers Are Going Mobile

Santander's Business Banking Customers Are Going Mobile

Bank Launches Self-Service Mobile App Exclusively for Business Customers; Adds New Functionality to its Consumer App to Improve the Customer Experience

RBS Warns of Another EC Deadline Miss as It Beats Profit Forecasts

RBS Warns of Another EC Deadline Miss as It Beats Profit Forecasts

Shares in the lender rise more than 4% in early trading.

European Stocks Slide As Oil Falls Back and Earnings Disappoint

European Stocks Slide As Oil Falls Back and Earnings Disappoint

U.K. lender Lloyds falls after a third-quarter profit miss, while luxury goods maker Kering surges.

Provisions, Restructuring News Top RBS Investors' Quarterly Wish List

Shareholders will also strain for information on the post-Brexit outlook at the Edinburgh lender.

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

UniCredit Shifts $1 Billion Bad Loan Portfolio Amid Italian Banking Shakeup

UniCredit Shifts $1 Billion Bad Loan Portfolio Amid Italian Banking Shakeup

The sale of a bad loan portfolio to Poland's Kruk follows projections of a pick-up in transactions in the second half of the year.

Santander Opens Its 19th Philadelphia Branch In The New Rodin Square Complex

Santander Opens Its 19th Philadelphia Branch In The New Rodin Square Complex

To Celebrate its Expanding Presence in Philadelphia, Santander Donates a Total of $12,000 to Three Community-Based Non-Profit Organizations

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

Deutsche Bank Tanks as Merkel Reportedly Nixes Aid

Deutsche Bank Tanks as Merkel Reportedly Nixes Aid

Shaky German banking giant gives up another 7%.

Angela Merkel Snub Report Adds to Deutsche's DoJ Woes

Angela Merkel Snub Report Adds to Deutsche's DoJ Woes

The struggling German bank is looking for Goldman Sachs-like penalties for its pre-crisis dealings.

Why It Won't Be Easy for Deutsche Bank to Cut Down $14 Billion U.S. Fine

Why It Won't Be Easy for Deutsche Bank to Cut Down $14 Billion U.S. Fine

The struggling German bank is looking for Goldman Sachs-like penalties for its pre-crisis dealings.

Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) In Clinical Trials

Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) In Clinical Trials

Sanofi and its specialty care global business unit Sanofi Genzyme announced today positive new six-year investigational data from the extension study of Lemtrada ® (alemtuzumab) in patients with relapsing...

Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme's Aubagio® (teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction

Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme's Aubagio® (teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced positive new real-world data from the Phase 4 Teri-PRO (Patient Reported Outcomes) study of Aubagio ®  (teriflunomide), a...